Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna L Forrest

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2018
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted AnalysisWasithep Limvorapitak, Michael J Barnett, Donna E Hogge, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Leukemia Research|September 3, 2008
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest, Shannon Trainor, Ryan R Brinkman, et al.
Blood|August 30, 2008
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancyCarolyn J Owen, Cynthia L Toze, Anna Koochin, et al.
Blood|April 10, 2020
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CMLHanyang Lin, Katharina Rothe, Min Chen, et al.
Stem Cell Reviews and Reports|June 5, 2025
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre ExperienceJowon L Kim, Moss A Bruton Joe, Shanee Chung, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Journal of the National Cancer Institute|March 1, 2013
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complexMin Chen, Paolo Gallipoli, Donna DeGeer, et al.
European Journal of Haematology|February 5, 2022
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohortRyan J Stubbins, Maria Stamenkovic, Claudie Roy, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2018
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted AnalysisWasithep Limvorapitak, Michael J Barnett, Donna E Hogge, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantationThomas J Nevill, John D Shepherd, Heather J Sutherland, et al.
Leukemia Research|September 3, 2008
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levelsDonna L Forrest, Shannon Trainor, Ryan R Brinkman, et al.
Blood|August 30, 2008
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancyCarolyn J Owen, Cynthia L Toze, Anna Koochin, et al.
Blood|April 10, 2020
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CMLHanyang Lin, Katharina Rothe, Min Chen, et al.
Stem Cell Reviews and Reports|June 5, 2025
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre ExperienceJowon L Kim, Moss A Bruton Joe, Shanee Chung, et al.
Blood|May 5, 2005
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in VancouverJulye C Lavoie, Joseph M Connors, Gordon L Phillips, et al.
Leukemia & Lymphoma|December 8, 2010
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)Christopher P Venner, Joseph M Connors, Heather J Sutherland, et al.
Journal of the National Cancer Institute|March 1, 2013
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complexMin Chen, Paolo Gallipoli, Donna DeGeer, et al.
European Journal of Haematology|February 5, 2022
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohortRyan J Stubbins, Maria Stamenkovic, Claudie Roy, et al.
Pageof 5